You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer
|
|---|---|
| Published in |
BMC Cancer, October 2015
|
| DOI | 10.1186/s12885-015-1779-7 |
| Pubmed ID | |
| Authors |
Julie Earl, Sandra Garcia-Nieto, Jose Carlos Martinez-Avila, José Montans, Alfonso Sanjuanbenito, Mercedes Rodríguez-Garrote, Eduardo Lisa, Elena Mendía, Eduardo Lobo, Núria Malats, Alfredo Carrato, Carmen Guillen-Ponce |
| Abstract |
Pancreatic cancer remains one of the most difficult cancers to treat with the poorest prognosis. The key to improving survival rates in this disease is early detection and monitoring of disseminated and residual disease. However, this is hindered due to lack reliable diagnostic and predictive markers which mean that the majority of patients succumb to their condition within a few months. We present a pilot study of the detection circulating free DNA (cfDNA) combined with tumor specific mutation detection by digital PCR as a novel minimally invasive biomarker in pancreatic ductal adenocarcinoma (PDAC). This was compared to the detection of CTC by the CellSearch® system and a novel CTC enrichment strategy based on CD45 positive cell depletion. The aim of the study was to assess tumor specific DNA detection in plasma and CTC detection as prognostic markers in PDAC. We detected KRAS mutant cfDNA in 26 % of patients of all stages and this correlated strongly with Overall Survival (OS), 60 days (95 % CI: 19-317) for KRAS mutation positive vs 772 days for KRAS mutation negative (95 % CI: 416-1127). Although, the presence of CTC detected by the CellSearch® system did correlate significantly with OS, 88 days (95 % CI: 27-206) CTC positive vs 393 days CTC negative (95 % CI: 284-501), CTC were detected in only 20 % of patients, the majority of which had metastatic disease, whereas KRAS mutant cfDNA was detected in patients with both resectable and advanced disease. Tumor specific cfDNA detection and CTC detection are promising markers for the management of patients with PDAC, although there is a need to validate these results in a larger patient cohort and optimize the detection of CTC in PDAC by applying the appropriate markers for their detection. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 180 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 2 | 1% |
| Ireland | 1 | <1% |
| Unknown | 177 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 35 | 19% |
| Student > Ph. D. Student | 27 | 15% |
| Student > Master | 19 | 11% |
| Other | 15 | 8% |
| Student > Bachelor | 14 | 8% |
| Other | 29 | 16% |
| Unknown | 41 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 64 | 36% |
| Biochemistry, Genetics and Molecular Biology | 23 | 13% |
| Agricultural and Biological Sciences | 20 | 11% |
| Engineering | 8 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
| Other | 12 | 7% |
| Unknown | 49 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 October 2015.
All research outputs
#19,054,237
of 23,613,071 outputs
Outputs from BMC Cancer
#5,567
of 8,487 outputs
Outputs of similar age
#206,232
of 284,967 outputs
Outputs of similar age from BMC Cancer
#141
of 222 outputs
Altmetric has tracked 23,613,071 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,487 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,967 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 222 others from the same source and published within six weeks on either side of this one. This one is in the 22nd percentile – i.e., 22% of its contemporaries scored the same or lower than it.